FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Alfredo Falcone, Elisa Sensi et al.|The Lancet Oncology|2015Cited by 1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerFotios Loupakis, Alfredo Falcone, Chiara Cremolini et al.|New England Journal of Medicine|2014Cited by 1.1k